Arbutus Biopharma CORP 10-Q quarterly reports

Arbutus Biopharma reports a substantial $178.4 million settlement payment from Moderna and positive clinical trial updates for its chronic hepatitis B therapeutic, imdusiran.

Arbutus Biopharma reports a significant financial turnaround driven by a $950 million noncontingent settlement payment from Moderna, leading to a substantial net income and a strong cash position.

Arbutus Biopharma reported significantly reduced net losses in Q3 2025, driven by cost-cutting and deferred revenue, while advancing its cHBV clinical programs and patent litigation.

Arbutus Biopharma reported a significant revenue increase and a swing to net income in Q2 2025, driven by a terminated partnership and substantial cost reductions, while advancing its cHBV pipeline and patent litigation.

Arbutus Biopharma announces Q1 2025 financial results, details operational restructuring, and provides updates on ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech.

Arbutus Biopharma reported its Q3 2024 financial results, highlighting a strategic shift towards advancing its hepatitis B virus (HBV) pipeline and a restructuring to streamline operations.

Arbutus Biopharma announced its second quarter 2024 financial results and a strategic restructuring to focus on key clinical programs and extend its cash runway into the fourth quarter of 2026.

Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, while advancing its hepatitis B virus (HBV) therapeutic pipeline and ongoing patent litigation.